The new Profarma Plan 2025‑2026, presented by the Ministry of Industry, Tourism and Health, becomes a key piece within the Strategic Plan of the Pharmaceutical Industry 2024-2028, with the purpose of placing Spain as a European leader in pharmaceutical production, research and health autonomy.
This program classifies pharmaceutical companies according to their performance in terms of industrial, economic and I+D+i, and grants reductions in contributions to the National Health System (SNS), which can reach until 25 %, with additional bonuses of the 10 % For companies participating in research consortiums or public-private collaborations.
Main novelties of the Profarma Plan 2025-2026
FOCUS IN STRATEGIC INNOVATION
The plan prioritizes projects related to Strategic, antimicrobial, biotechnological medicines, advanced therapies and drugs with lower environmental impact. In addition, it values the research activity linked to digital innovation centers and the use of disruptive technologies, such as artificial intelligence.
Comprehensive Evaluation of Companies
Companies are evaluated by their productive capacity, their investments in R&D, their commitment to the sustainability and his Contribution to the strategic autonomy of the country. Participations are also valued in projects with biotechnological startups and public or private research centers.
Validity and updated procedure
Unlike previous more prolonged cycles, the 2025-2026 program is structured in biennial calls. The deadline for submitting applications for 2025 ends on October 15, while the call of 2026 will open from June 15 to September 15 of that year.
Strategic context and sector value
The profarma plan is integrated into a broader vision of the government to reinforce the pharmaceutical sector as Economic and Sanitary Pilar. The global strategy of the 2024-2028 period aspires to reduce external dependence, strengthen national production and expedite innovation, consolidating Spain as a European reference in clinical trials and drug manufacturing.
This impulse arrives at a crucial moment: Spain has already attracted 9,000 million euros of investment in the pharmaceutical sector In the first years of the strategic plan, reflecting the value of the country as a platform for multinationals in the sector.
Opportunities for companies in the sector
| Key benefit | Description |
| Lower regulatory load | Reduction of up to 25% in contributions to the SNS according to the profarma rating. |
| IMPULSE TO R&D | Additional bonus for participation in innovation consortiums. |
| Visibility and reputation | Excellence certification valued by partners and authorities. |
| Support for sustainability and modernization | Recognition of projects with environmental and technological impact. |
| Greater competitiveness and investment | It stimulates that subsidiaries and large laboratories invest in Spain. |
The Profarma Plan 2025-2026 returns as a strategic tool that combines tax incentives with public -private recognition. Aligning industrial capacities with innovation and sustainability is the way to strengthen the health autonomy of Spain, favor the growth of the sector and generate qualified employment.
For national and internationalized pharmaceutical companies, participating in Profarma is not just a tax reduction opportunity: it is a Competitive Declaration of Industrial, Technological and Strategic Commitment.